Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Bile duct segmental resection versus pancreaticoduodenectomy for middle-third extrahepatic cholangiocarcinoma: A propensity-matched, single-center retrospective analysis.

Annals of hepato-biliary-pancreatic surgery·2026
Same author

Robotic single-port plus one-port radical cholecystectomy: description of surgical techniques with video.

Journal of minimally invasive surgery·2026
Same author

Expert Survey on Chyle Leakage After Pancreaticoduodenectomy: The Precision Anatomy for Minimally Invasive Hepato-Biliary-Pancreatic Surgery (PAM-HBP Surgery) Project 2024.

Journal of hepato-biliary-pancreatic sciences·2026
Same author

Reduced port robotic cholecystectomy using the Revo-i single-site plus ONE port approach: a case series with video.

Journal of minimally invasive surgery·2026
Same author

Long-term oncologic outcomes and prognostic factors in resected stage IA pancreatic cancer: a retrospective cohort study.

Surgical endoscopy·2026
Same author

Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future use as an indication for neoadjuvant treatment: a retrospective multicenter cohort study.

Annals of surgical treatment and research·2026

相关实验视频

Updated: Jun 25, 2025

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.3K

葡萄糖与淋巴细胞的比率 (GLR) 作为患者的独立预后因素切除胰腺管道腺癌-队列研究.

Su-Hyeong Park1, In-Cheon Kang2, Seung-Soo Hong3,4

  • 1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon 22711, Republic of Korea.

Cancers
|May 25, 2024
PubMed
概括

葡萄糖与淋巴细胞比率 (GLR) 的升高预测胰腺癌患者的生存率不佳. 这种手术前生物标志物,以及瘤标志物和症状,有助于识别胰腺管腺癌 (PDAC) 的高风险个体,需要更密切的监测.

关键词:
标记 标记 标记 标记 标记 标记胰腺癌是一种癌症.胰腺管道腺癌瘤胰腺瘤的发生.幸存率 幸存率 生存率

更多相关视频

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K

相关实验视频

Last Updated: Jun 25, 2025

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

4.3K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K

科学领域:

  • 在瘤学瘤学.
  • 生物标志物 生物标志物
  • 手术瘤学手术瘤学

背景情况:

  • 胰腺管腺癌 (PDAC) 仍然是一个具有挑战性的恶性瘤,预后不佳.
  • 确定可靠的预后生物标志物用于早期风险分层是改善患者结果的关键.

研究的目的:

  • 评估PDAC患者进行手术切除时葡萄糖与淋巴细胞比率 (GLR) 升高的预后值.
  • 确定PDAC患者疾病特异性生存的术前预测因素.

主要方法:

  • 对338名经过手术切除的PDAC患者进行了回顾性分析.
  • 使用Contal和O'Quigley方法确定最佳GLR切割值.
  • 多变量分析以确定长期生存的独立预测因素.

主要成果:

  • 升高的GLR与侵袭性瘤特征相关,包括高CA 19-9水平和更大的瘤大小.
  • 预后不佳的独立预测因素是GLR>92.72,CA 19-9>145.35,以及症状的存在.
  • 根据这些因素,患者被分为三组,显示出明显不同的5年生存率 (50.2%,34.6%和11.7%).

结论:

  • 术前GLR升高是PDAC患者预后不佳的重要独立预测因素.
  • GLR与其他临床因素相结合,有助于风险分层和预后.
  • 需要进一步的前性研究来验证这些发现.